Skip to content
Menu

Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.

Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.

Read at benzinga.com

← All stock news